<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="152927">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01750190</url>
  </required_header>
  <id_info>
    <org_study_id>FGCL-4592-060</org_study_id>
    <nct_id>NCT01750190</nct_id>
  </id_info>
  <brief_title>A Study of FG-4592 for the Treatment of Anemia in Chronic Kidney Disease Patients Not Receiving Dialysis</brief_title>
  <official_title>A Phase 3, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of FG-4592 for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FibroGen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma Europe B.V.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>FibroGen</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Malaysia: Ministry of Health</authority>
    <authority>Taiwan : Food and Drug Administration</authority>
    <authority>Korea: Ministry of Food and Drug Safety</authority>
    <authority>Hong Kong: Department of Health</authority>
    <authority>Thailand: Food and Drug Administration</authority>
    <authority>Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica</authority>
    <authority>Chile: Ministry of Health</authority>
    <authority>Mexico: Federal Commission for Protection Against Health Risks</authority>
    <authority>Peru: General Directorate of Pharmaceuticals, Devices, and Drugs</authority>
    <authority>Brazil: National Health Surveillance Agency</authority>
    <authority>Colombia: INVIMA Instituto Nacional de Vigilancia de Medicamentos y Alimentos</authority>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <authority>Singapore: Health Sciences Authority</authority>
    <authority>Philippines : Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of FG-4592 in the treatment
      of anemia of Chronic Kidney Disease (CKD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is a screening period of up to 6 weeks, a treatment period of 52 weeks, and a
      post-treatment follow up period of 4 weeks. A total of 450-600 patients will be randomized
      in a 2:1 ratio to receive either FG-4592 or Placebo in blinded fashion.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Efficacy of FG-4592 - anemia correction</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Efficacy of FG-4592 in achieving hemoglobin response (as defined in protocol) in CKD subjects not receiving dialysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of FG-4592 - Maintenance of hemoglobin levels</measure>
    <time_frame>52 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the need for anemia rescue therapy, such as blood transfusion, intravenous Iron, or injectable erythrocyte stimulating therapies</measure>
    <time_frame>52 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of FG-4592</measure>
    <time_frame>52 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Evaluate changes in vital signs and laboratory values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FG-4592 Tolerability</measure>
    <time_frame>52 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Evaluate Adverse Events (AE) and Serious Adverse Events (SAE)</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>FG-4592 (TIW &amp; BIW)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study drug will be dosed TIW during the correction period, then twice weekly (BIW) during the maintenance period. Dose adjustments are allowed during the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (TIW &amp; TIW)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Study drug will be dosed TIW during the correction period and TIW during the maintenance period. Dose adjustments are allowed during the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FG-4592 (TIW &amp; TIW)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study drug will be dosed three times weekly (TIW) during the correction period and TIW during the maintenance period. Dose adjustments are allowed during the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FG-4592 (TIW &amp; QW)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study drug will be dosed TIW during the correction period, then weekly (QW) during the maintenance period. Dose adjustments are allowed during the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (TIW &amp; BIW)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Study drug will be dosed TIW during the correction period and BIW during the maintenance period. Dose adjustments are allowed during the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (TIW &amp; QW)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Study drug will be dosed TIW during the correction period and QW during the maintenance period. Dose adjustments are allowed during the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FG-4592</intervention_name>
    <description>Oral</description>
    <arm_group_label>FG-4592 (TIW &amp; BIW)</arm_group_label>
    <arm_group_label>FG-4592 (TIW &amp; TIW)</arm_group_label>
    <arm_group_label>FG-4592 (TIW &amp; QW)</arm_group_label>
    <other_name>Roxadustat; ASP1517</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral</description>
    <arm_group_label>Placebo (TIW &amp; TIW)</arm_group_label>
    <arm_group_label>Placebo (TIW &amp; BIW)</arm_group_label>
    <arm_group_label>Placebo (TIW &amp; QW)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic kidney disease,  Stage 3, 4, or 5, not receiving dialysis

          -  Anemia qualified by measurements of hemoglobin values during screening

          -  Additional blood work must be in a safe range for study entry

          -  Body weight 45 to 160 kg

          -  Willingness to use contraception if of child-bearing potential

        Exclusion Criteria:

          -  Treatment with an erythropoiesis-stimulating agent within 12 weeks prior to study
             participation

          -  More than one dose of intravenous iron within 12 weeks prior to study participation

          -  Blood transfusion within 8 weeks prior to study participation

          -  Active infection

          -  Chronic liver disease

          -  Severe congestive heart failure, recent heart attack, stroke, seizure, or blood clot

          -  Uncontrolled blood pressure within 2 weeks prior to study participation

          -  Renal cell carcinoma

          -  History of malignancy, including multiple myeloma or other myelodysplastic syndrome

          -  Chronic inflammatory disease that could impact red blood cell production

          -  Any prior organ transplant, or a scheduled organ transplantation

          -  Anticipated elective surgery that is expected to lead to significant blood loss, or
             anticipated elective heart procedure

          -  Gastrointestinal bleeding

          -  Any prior treatment with FG-4592 or a HIF-PHI

          -  Recent use of an investigational drug or treatment, or participation in an
             investigational study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Bradley, PhD</last_name>
    <role>Study Director</role>
    <affiliation>FibroGen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trial Coordinator</last_name>
    <phone>1-415-978-1672</phone>
    <email>060study@fibrogen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91910</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91325</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Yuba City</city>
        <state>California</state>
        <zip>95991</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Sao Paolo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Selayang</city>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>San Luis Potosi</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Pasig</city>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Hong Kong</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>New Zealand</country>
    <country>Peru</country>
    <country>Philippines</country>
    <country>Singapore</country>
    <country>Taiwan</country>
    <country>Thailand</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 31, 2014</lastchanged_date>
  <firstreceived_date>December 11, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anemia</keyword>
  <keyword>chronic kidney disease (CKD)</keyword>
  <keyword>non-dialysis</keyword>
  <keyword>Hemoglobin (Hb)</keyword>
  <keyword>End-Stage Renal Disease</keyword>
  <keyword>Erythropoeitin</keyword>
  <keyword>ASP1517</keyword>
  <keyword>Erythropoeisis stimulating-agent</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
